BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BC Extra | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb   Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP)...
BC Extra | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal  Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR...
BC Extra | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
BC Extra | Jul 9, 2019
Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
BC Extra | May 14, 2019
Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data  Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
BC Week In Review | Mar 29, 2019
Clinical News

Opko's diabetes therapy meets in Phase IIb

Opko said OPK88003 met the primary endpoint in a Phase IIb trial to treat adult Type II diabetics who had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK)...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
BC Week In Review | Sep 21, 2018
Clinical News

Zealand's hypoglycemia candidate meets in second Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a second Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation...
BC Week In Review | Jul 6, 2018
Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs....
Items per page:
1 - 10 of 91